Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
暂无分享,去创建一个
J. Shih | S. Peters | G. Chang | J. Yang | H. Nechushtan | V. Spataro | R. Lorence | M. Unk | A. Curioni-Fontecedro | O. Gautschi | W. Liao | P. Carrière | A. Cseh